Senzime AB reports recurring developments around its TetraGraph neuromuscular monitoring system, hospital contracting in the United States, and commercialization through integrated delivery networks and group purchasing organizations. Company updates also cover TetraCom connectivity, financial reports, margin and cash-flow commentary, and expansion of U.S. sales, clinical, and medical-affairs functions.
Governance-related announcements include annual general meeting notices and shareholder-program proposals, while operating updates focus on anesthesia data transmission, hospital procurement access, system installations, and recurring revenue tied to the installed base.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.81%
Tags
FAQ
What is the current stock price of SENZIME AB (SNZZF)?
SENZIME AB (SNZZF) last closed at $0.2352.
What is the market cap of SENZIME AB (SNZZF)?
The market cap of SENZIME AB (SNZZF) is approximately $46.3M.